BioSpace News Archive

As COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity.

Unity Health Care has been designated as a COVID-19 vaccine distribution partner to support continued COVID-19 vaccination efforts in the DC region and around the country.

Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. and is characterized by extremely high low-density lipoprotein cholesterol (LDL-C)

Adara Acquisition Corp. (the “Company”), a newly incorporated blank check company, today announced that it closed its initial public offering of 11,500,000 units, including 1,500,000 sold pursuant to the full exercise of the underwriters’ over-allotment option, at $10.00 per unit.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 25, 2021 at 4:00 PM Eastern Time.

AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, reported financial results for its second quarter of fiscal year 2021, ended December 31, 2020.

Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the pricing of its initial public offering of 7,062,000 shares of its common stock at a price to the public of $18.00 per share.

Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX) (the “Company”), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system,

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company